Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN9A | Q15858 | 18/20 | 0.51 |
| ▸ | SCN10A | Q9Y5Y9 | 2/20 | 0.50 |
| ▸ | SCN7A | Q01118 | 3/20 | 0.48 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.48 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.45 |
| ▸ | MAPK7 | Q13164 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1807553 | 0.89 | SCN9A (0.47) | SCN9ASCN10ASCN7AKCNH2 | |
| SCHEMBL12188743 | 0.87 | SCN9A (0.49) | SCN9ASCN7AKCNH2HRH3 | |
| SCHEMBL1806244 | 0.82 | SCN9A (0.46) | SCN9ASCN10ASCN7AKCNH2 | |
| SCHEMBL1809041 | 0.81 | SCN9A (0.50) | SCN9ASCN10ASCN7AKCNH2HRH3 | |
| SCHEMBL1809328 | 0.80 | SMN1; SMN2 (0.50) | SCN9ASCN10ASCN7AKCNH2 | |
| SCHEMBL12100279 | 0.77 | ELOVL6 (0.38) | SCN9ASCN10AHRH3MAPK7 | |
| SCHEMBL1808102 | 0.76 | CACNA1B (0.48) | SCN9AKCNH2 | |
| SCHEMBL1810294 | 0.74 | SCN9A (0.45) | SCN9ASCN10ASCN7AKCNH2MAPK7 | |
| SCHEMBL3038099 | 0.74 | CACNA1B (0.61) | SCN9AMAPK7 | |
| SCHEMBL1807148 | 0.74 | GPR119 (0.51) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9051296-B2 | Aryl carboxamide derivatives as TTX-S blockers | RAQUALIA PHARMA INC. (JP) | 2015-06-09 | — | — | US | claimed |
| US-20120232052-A1 | ARYL CARBOXAMIDE DERIVATIVES AS TTX-S BLOCKERS | RAQUALIA PHARMA INC. (JP) | 2012-09-13 | — | — | US | claimed |
| WO-2011058766-A1 | ARYL CARBOXAMIDE DERIVATIVES AS TTX-S BLOCKERS | RAQUALIA PHARMA INC. (JP) | 2011-05-19 | — | — | WO | claimed |
| US-9051296-B2 | Aryl carboxamide derivatives as TTX-S blockers | RAQUALIA PHARMA INC. (JP) | 2015-06-09 | — | — | US | disclosed |
| US-9051296-B2 | Aryl carboxamide derivatives as TTX-S blockers | RAQUALIA PHARMA INC. (JP) | 2015-06-09 | — | — | US | disclosed |
| US-9051296-B2 | Aryl carboxamide derivatives as TTX-S blockers | RAQUALIA PHARMA INC. (JP) | 2015-06-09 | — | — | US | disclosed |
| US-20120232052-A1 | ARYL CARBOXAMIDE DERIVATIVES AS TTX-S BLOCKERS | RAQUALIA PHARMA INC. (JP) | 2012-09-13 | — | — | US | disclosed |
| US-20120232052-A1 | ARYL CARBOXAMIDE DERIVATIVES AS TTX-S BLOCKERS | RAQUALIA PHARMA INC. (JP) | 2012-09-13 | — | — | US | disclosed |
| WO-2011058766-A1 | ARYL CARBOXAMIDE DERIVATIVES AS TTX-S BLOCKERS | RAQUALIA PHARMA INC. (JP) | 2011-05-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120232052-A1 | ARYL CARBOXAMIDE DERIVATIVES AS TTX-S BLOCKERS | SCN1B, SCN1A, SCN2B | SCN9A 20/4885SCN10A 14/4885SCN7A 16/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.